Crispr Therapeutics shares tumble after significant earnings miss
Amir Rosenthal, a director at Sturm Ruger & Co Inc (NYSE:RGR), recently sold 500 shares of the company's common stock. The shares were sold at a price of $35.64 each, totaling $17,820. This transaction, completed on January 2, 2025, was part of a pre-established Rule 10b5-1 trading plan that Rosenthal adopted in August 2024. Following the sale, Rosenthal retains ownership of 17,054 shares in the company.
In other recent news, Sturm, Ruger & Company, Inc. reported mixed financial results for the third quarter of 2024. The firearms manufacturer showed a slight increase in net sales, rising from $120.9 million in the same quarter of the previous year to $122.3 million. However, diluted earnings per share decreased from $0.42 in the third quarter of 2023 to $0.28 in the same period of 2024. The company maintains a robust financial position with $96 million in cash and short-term investments and no debt.
Sturm, Ruger also announced upcoming changes to its board leadership, with John A. Cosentino, Jr. set to succeed Ronald C. Whitaker as the Chairman of the Board, effective January 1, 2025. Phillip C. Widman will take over Mr. Cosentino's role as the Lead Vice-Chairman of the Board. In other developments, the company has updated severance agreements with key executive officers and returned $39.3 million to its shareholders in the first nine months of 2024 through dividends and stock repurchases.
These are the recent developments for Sturm, Ruger & Company, Inc. Investors may view these changes as part of the company's commitment to innovation and strategic growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.